{
  "id": 16120131,
  "title": "Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?",
  "url": "https://urgent.news/2026/10/22/amgen-vs-eli-lilly-does-the-glp-1-mania-make-lly-stock-a-better-buy-16120131",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T22:15:02.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/amgen-vs-eli-lilly-does-glp-1-mania-make-lly-stock-better-buy-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsAmgen maintains a diverse portfolio focused on oncology, rare diseases, and inflammation while providing steady cash flow generation.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?",
        "url": "https://urgent.news/2026/10/22/amgen-vs-eli-lilly-does-the-glp-1-mania-make-lly-stock-a-better-buy",
        "published": "2026-10-22T21:55:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}